|
|
Exchange: |
New York Stock Exchange |
Security
Type: |
Common |
Shares
Out: |
2,250,000,000 |
Market
Cap: |
93.44(B) |
Last
Volume: |
20,542,542 |
Avg
Vol: |
12,077,193 |
52
Week Range: |
$40.25 - $64.73 |
|
Level
I Sector: |
Health Care |
Level
II Sector: |
Drugs |
Level
III Sector: |
Drug Manufacturers - Major |
|
Member Indexes:
|
S&P COMPOSITE 1500 |
|
NYSE COMPOSITE |
|
S&P 100 |
|
S&P 500 |
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : 97 |
Guru Rank Value : 8.6 |
Guru Occurances : 3 |
|
|
|
|
|
|
|
Company Profile Bristol-Myers Squibb is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products on a global basis. Co.'s primary products include: Revlimid®, in which Revlimid (lenalidomide) is an oral immunomodulatory drug that in combination with dexamethasone is indicated for the treatment of patients with multiple myeloma; and Eliquis®, in which Eliquis (apixaban) is an oral Factor Xa inhibitor indicated for the reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation and for the treatment of DVT/PE and reduction in risk of recurrence following initial therapy.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
13,571 |
13,571 |
Total Buy Value |
$0 |
$0 |
$672,994 |
$672,994 |
Total People Bought |
0 |
0 |
2 |
2 |
Total Buy Transactions |
0 |
0 |
3 |
3 |
Total Shares Sold |
0 |
0 |
18,718 |
616,397 |
Total Sell Value |
$0 |
$0 |
$1,146,397 |
$44,859,834 |
Total People Sold |
0 |
0 |
2 |
5 |
Total Sell Transactions |
0 |
0 |
2 |
11 |
End Date |
2024-03-31 |
2023-12-29 |
2023-06-30 |
2022-06-30 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Andreotti Lamberto |
Director |
|
2016-03-09 |
4 |
AS |
$65.35 |
$758,260 |
D/D |
(11,600) |
369,654 |
|
- |
|
Andreotti Lamberto |
Director |
|
2016-03-08 |
4 |
AS |
$66.06 |
$766,296 |
D/D |
(11,600) |
381,254 |
|
- |
|
Campbell Lewis B |
Director |
|
2016-03-08 |
4 |
S |
$66.00 |
$165,000 |
D/D |
(2,500) |
0 |
|
- |
|
Campbell Lewis B |
Director |
|
2016-03-08 |
4 |
OE |
$24.96 |
$62,400 |
D/D |
2,500 |
2,500 |
|
- |
|
Leung Sandra |
EVP, General Counsel |
|
2016-03-06 |
4 |
D |
$64.71 |
$363,864 |
D/D |
(5,623) |
314,801 |
|
- |
|
Leung Sandra |
EVP, General Counsel |
|
2016-03-06 |
4 |
A |
$0.00 |
$0 |
D/D |
5,303 |
320,424 |
|
- |
|
Leung Sandra |
EVP, General Counsel |
|
2016-03-06 |
4 |
OE |
$0.00 |
$0 |
D/D |
5,574 |
315,121 |
|
- |
|
Bancroft Charles A |
EVP & Chief Financial Officer |
|
2016-03-06 |
4 |
D |
$64.71 |
$416,409 |
D/D |
(6,435) |
170,418 |
|
- |
|
Bancroft Charles A |
EVP & Chief Financial Officer |
|
2016-03-06 |
4 |
A |
$0.00 |
$0 |
D/D |
6,968 |
176,853 |
|
- |
|
Bancroft Charles A |
EVP & Chief Financial Officer |
|
2016-03-06 |
4 |
OE |
$0.00 |
$0 |
D/D |
7,324 |
169,885 |
|
- |
|
Elicker John E |
SVP, Public Affairs & IR |
|
2016-03-06 |
4 |
D |
$64.71 |
$40,120 |
D/D |
(620) |
54,087 |
|
- |
|
Elicker John E |
SVP, Public Affairs & IR |
|
2016-03-06 |
4 |
A |
$0.00 |
$0 |
D/D |
992 |
54,707 |
|
- |
|
Elicker John E |
SVP, Public Affairs & IR |
|
2016-03-06 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,043 |
53,715 |
|
- |
|
Blin Emmanuel |
SVP, Head of Commercialization |
|
2016-03-06 |
4 |
D |
$64.71 |
$23,813 |
D/D |
(368) |
1,964 |
|
- |
|
Blin Emmanuel |
SVP, Head of Commercialization |
|
2016-03-06 |
4 |
A |
$0.00 |
$0 |
D/D |
779 |
2,332 |
|
- |
|
Blin Emmanuel |
SVP, Head of Commercialization |
|
2016-03-06 |
4 |
OE |
$0.00 |
$0 |
D/D |
819 |
1,553 |
|
- |
|
Von Autenried Paul |
SVP, Enterp. Services & CIO |
|
2016-03-06 |
4 |
D |
$64.71 |
$112,531 |
D/D |
(1,739) |
60,568 |
|
- |
|
Von Autenried Paul |
SVP, Enterp. Services & CIO |
|
2016-03-06 |
4 |
A |
$0.00 |
$0 |
D/D |
2,275 |
62,307 |
|
- |
|
Von Autenried Paul |
SVP, Enterp. Services & CIO |
|
2016-03-06 |
4 |
OE |
$0.00 |
$0 |
D/D |
2,391 |
60,032 |
|
- |
|
Cuss Francis M |
EVP & CSO |
|
2016-03-06 |
4 |
D |
$64.71 |
$197,107 |
D/D |
(3,046) |
268,861 |
|
- |
|
Cuss Francis M |
EVP & CSO |
|
2016-03-06 |
4 |
A |
$0.00 |
$0 |
D/D |
2,864 |
271,907 |
|
- |
|
Cuss Francis M |
EVP & CSO |
|
2016-03-06 |
4 |
OE |
$0.00 |
$0 |
D/D |
3,010 |
269,043 |
|
- |
|
Schmukler Louis S |
Pres., Global Mfg. & Supply |
|
2016-03-06 |
4 |
D |
$64.71 |
$101,077 |
D/D |
(1,562) |
25,589 |
|
- |
|
Schmukler Louis S |
Pres., Global Mfg. & Supply |
|
2016-03-06 |
4 |
A |
$0.00 |
$0 |
D/D |
2,405 |
27,151 |
|
- |
|
Schmukler Louis S |
Pres., Global Mfg. & Supply |
|
2016-03-06 |
4 |
OE |
$0.00 |
$0 |
D/D |
2,528 |
24,746 |
|
- |
|
953 Records found
|
|
Page 29 of 39 |
|
|